124 related articles for article (PubMed ID: 31323236)
21. Tackling influenza with broadly neutralizing antibodies.
Corti D; Cameroni E; Guarino B; Kallewaard NL; Zhu Q; Lanzavecchia A
Curr Opin Virol; 2017 Jun; 24():60-69. PubMed ID: 28527859
[TBL] [Abstract][Full Text] [Related]
22. Cross-clade antibody reactivity may attenuate the ability of influenza virus to evade the immune response.
Vashisht S; Verma S; Salunke DM
Mol Immunol; 2019 Oct; 114():149-161. PubMed ID: 31352231
[TBL] [Abstract][Full Text] [Related]
23. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
24. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
[TBL] [Abstract][Full Text] [Related]
25. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.
Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F
mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832
[TBL] [Abstract][Full Text] [Related]
26. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
27. Stalking influenza by vaccination with pre-fusion headless HA mini-stem.
Valkenburg SA; Mallajosyula VV; Li OT; Chin AW; Carnell G; Temperton N; Varadarajan R; Poon LL
Sci Rep; 2016 Mar; 6():22666. PubMed ID: 26947245
[TBL] [Abstract][Full Text] [Related]
28. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.
Mullarkey CE; Bailey MJ; Golubeva DA; Tan GS; Nachbagauer R; He W; Novakowski KE; Bowdish DM; Miller MS; Palese P
mBio; 2016 Oct; 7(5):. PubMed ID: 27703076
[TBL] [Abstract][Full Text] [Related]
29. Broadly neutralizing antibodies recognizing different antigenic epitopes act synergistically against the influenza B virus.
Zhai L; Zhang L; Jiang Y; Li B; Yang M; Victorovich KV; Aleksandrovna KT; Li M; Wang Y; Huang D; Zeng Z; Ren Z; Cao H; Zhu L; Wu Q; Xiao W; Zhang B; Wan C; Wang F; Xia N; Zhao W; Chen Y; Shen C
J Med Virol; 2023 Jan; 95(1):e28106. PubMed ID: 36039848
[TBL] [Abstract][Full Text] [Related]
30. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
31. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.
Shen C; Zhang M; Chen Y; Zhang L; Wang G; Chen J; Chen S; Li Z; Wei F; Chen J; Yang K; Guo S; Wang Y; Zheng Q; Yu H; Luo W; Zhang J; Chen H; Chen Y; Xia N
Theranostics; 2019; 9(1):210-231. PubMed ID: 30662563
[TBL] [Abstract][Full Text] [Related]
32. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
Krammer F; Palese P
J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
[TBL] [Abstract][Full Text] [Related]
33. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
Front Immunol; 2018; 9():2350. PubMed ID: 30369928
[TBL] [Abstract][Full Text] [Related]
34. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
[TBL] [Abstract][Full Text] [Related]
35. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
36. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.
Bangaru S; Zhang H; Gilchuk IM; Voss TG; Irving RP; Gilchuk P; Matta P; Zhu X; Lang S; Nieusma T; Richt JA; Albrecht RA; Vanderven HA; Bombardi R; Kent SJ; Ward AB; Wilson IA; Crowe JE
Nat Commun; 2018 Jul; 9(1):2669. PubMed ID: 29991715
[TBL] [Abstract][Full Text] [Related]
37. Divergent Requirement of Fc-Fcγ Receptor Interactions for
Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
[TBL] [Abstract][Full Text] [Related]
38. Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge.
Kuenstling TE; Sambol AR; Hinrichs SH; Larson MA
Sci Rep; 2018 Aug; 8(1):11856. PubMed ID: 30087372
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
40. An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice.
Kim EH; Han GY; Nguyen H
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
